Skip to main content
. 2009 May 20;83(15):7706–7717. doi: 10.1128/JVI.00683-09

FIG. 3.

FIG. 3.

Experimental design of the two in vivo studies with GSK501015 in hCD4/hCCR5-transgenic rats. (A) High-dose study. Transgenic rats were treated with GSK501015 at 10 mg/kg by twice-daily oral gavage for 5 days (GSK501015 group; n = 6) or left untreated (control group; n = 6). On day 1, the animals, including one hCD4 single-transgenic rat (ID 940), were challenged with HIV-1YU-2 by tail vein injection. On day 4 postinfection, the animals were sacrificed and their spleens were removed for the quantitative analysis of HIV-1 cDNA species. (B) Dose titration study. hCD4/hCCR5 transgenic rats were treated with GSK501015 at the indicated doses for 5 days or left untreated. On day 1, the animals, including one nontransgenic rat and one hCCR5 transgenic rat, were challenged with HIV-1YU-2 by tail vein injection. On day 4 postinfection, the animals were sacrificed and their spleens were removed for the quantitative analysis of HIV-1 cDNA species. Blood samples for concurrent pharmacokinetic analysis were taken from all INI-treated animals on the indicated days at −2 h, +2 h, and +6 h relative to the morning dosing.